Pharmaceutical News

RSS

Swedish scientists discover a new method to develop effective antimalarial drugs

Amodiaquine was introduced as an antimalarial drug, but was withdrawn when serious adverse effects were observed. Scientists at the University of Gothenburg, Sweden, have now developed a method that can be used to develop safer drugs.

10 May 2010

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain.

7 May 2010

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

Arena Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

NPWH launches ETIQ campaign to improve access to information about menopause, estrogen therapy

The National Association of Nurse Practitioners in Women's Health announced the launch of Estrogen Therapy I.Q. a campaign devoted to improving access to credible information about menopause and advances in estrogen therapy.

7 May 2010

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the first quarter ended March 31, 2010. The Company also highlighted key commercial and regulatory progress during the quarter, and provided its expected milestones for the remainder of 2010.

7 May 2010

New changes to 'Extra Help' program enables more people save on prescription drug costs

Medicare beneficiaries who qualify for "Extra Help" may be eligible to pay no more than $2.50 for generic drugs and $6.30 for each brand name drug thanks to changes to Medicare's Low-Income Subsidy Program for Part D prescription drug costs (also known as LIS or "Extra Help") that take effect this year. These changes make it easier than ever for people on Medicare with limited incomes to save on their drug costs.

7 May 2010

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Keryx Biopharmaceutical Inc. The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.

7 May 2010

Town hall meeting to address negative health, societal consequences of methamphetamine abuse

Pan American Bank (Los Angeles) today announced that it has partnered with the UCLA Youth Methamphetamine Treatment Study, LatinoGraduate.net and The Wall-Las Memorias Project to host a town hall meeting that addresses the negative health and societal consequences of methamphetamine abuse by Latino youth.

7 May 2010

Intellipharmaceutics generic Effexor XR ANDA accepted for filing by the FDA

Intellipharmaceutics International Inc., today announced that the Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of the antidepressant Effexor XR® (venlafaxine hydrochloride).

7 May 2010

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $210,300 to Amicus Therapeutics (Cranbury, NJ) to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer's disease.

7 May 2010

Meda acquires exclusive rights for use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals

Meda has acquired exclusive US, Canadian and Japanese rights for the use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals. As part of the agreement, Meda is taking over full responsibility for development and commercialization of the compound. Flupirtine is currently in phase II development for the patented indication fibromyalgia.

7 May 2010

Progestins increase chances of cancer metastasizing: Study

After menopause, 6 to 10 million women take hormone therapies, which are often a combination of estrogen and progestin, to replace hormones lost from inactive ovaries. Progestin is a hormone that is used to counteract the potentially negative effects of estrogen therapy on the uterus. In studies sponsored by the National Institutes of Health, evidence has been found that estrogen and progestin in hormone therapies increase the risk of breast cancer in post-menopausal women.

7 May 2010

Merrion Pharmaceuticals increases patent protection for Orazol

Merrion Pharmaceuticals plc, a pharmaceutical development company, today announces that it has been granted a further U.S. Patent, increasing the protection for their lead product, Orazol™.

7 May 2010

Judge's ruling gives 'wide latitude' to plaintiffs' in lawsuits against Omniscan imaging drug

ProPublica: In a key ruling, "a federal judge has given plaintiffs' lawyers wide latitude to present evidence and expert testimony that GE's Omniscan imaging drug caused a crippling disease in MRI patients."

7 May 2010

Natazia tablets receive FDA approval for prevention of pregnancy

Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.

7 May 2010

The Forum calls upon pharma suppliers, distributors, pharmacies to stop distribution of unapproved drugs

Gary Puckrein, President and CEO of the National Minority Quality Forum (The Forum), recently sent a letter to the CEOs of eight major pharmaceutical suppliers, distributors and pharmacies to educate them on the potential threats posed by unapproved drugs in the United States and to ask that they do their part to protect consumers from the harms that can be caused by these unproven products.

7 May 2010

Sun Pharmaceutical subsidiary granted USFDA approval for generic Namenda tablets

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.

7 May 2010

$DMPA injectible contraceptive associated with increased risk of bone fracture$

DMPA injectible contraceptive associated with increased risk of bone fracture

A new study presented today at the World Congress on Osteoporosis (IOF WCO-ECCEO10) in Florence, Italy shows that DMPA, a commonly used injectible contraceptive, is associated with higher risk of bone fracture when used alone, and not in combination with estrogens.

7 May 2010

FDA approves new oral contraceptive Natazia

The U.S. Food and Drug Administration today approved Natazia, a combination hormonal tablet for use as an oral contraceptive.

7 May 2010

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Abraxis BioScience, Inc., a fully integrated biotechnology company, today reported unaudited financial results for the first quarter ended March 31, 2010.

6 May 2010

Pharmaceutical News

Swedish scientists discover a new method to develop effective antimalarial drugs

Data comparing NUCYNTA to oxycodone IR for osteoarthritis pain presented at 29th APS

Arena Pharmaceuticals reports lower net loss of $31.3 million in first-quarter 2010

NPWH launches ETIQ campaign to improve access to information about menopause, estrogen therapy

BioSpecifics Technologies total revenues for first-quarter increase to $2.7M

New changes to 'Extra Help' program enables more people save on prescription drug costs

Investment report on Keryx Biopharmaceutical from MicroStockProfit.com

Town hall meeting to address negative health, societal consequences of methamphetamine abuse

Intellipharmaceutics generic Effexor XR ANDA accepted for filing by the FDA

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

Meda acquires exclusive rights for use of flupirtine to treat fibromyalgia from Adeona Pharmaceuticals

Progestins increase chances of cancer metastasizing: Study

Merrion Pharmaceuticals increases patent protection for Orazol

Judge's ruling gives 'wide latitude' to plaintiffs' in lawsuits against Omniscan imaging drug

Natazia tablets receive FDA approval for prevention of pregnancy

The Forum calls upon pharma suppliers, distributors, pharmacies to stop distribution of unapproved drugs

Sun Pharmaceutical subsidiary granted USFDA approval for generic Namenda tablets

DMPA injectible contraceptive associated with increased risk of bone fracture

FDA approves new oral contraceptive Natazia

Abraxis Bioscience first-quarter ABRAXANE revenue increases to $87.9 million

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News